09:00 am Online Registration & Virtual Coffee
9:15 am Chair’s Opening Remark
Supercharging Fundamental Knowledge in γδ T Biology to Unveil their Full Potential
9:30 am Understanding Vg9Vd2 Activation: What is Known and the Rest
Synopsis
• Outlining the molecular basis of Vg9Vd2 T cell activation
• Exploring the role of Vg9Vd2 in cancer settings
• Discussing questions regarding regulation
10:00 am Either/Or or Both/And – The Delta One vs. Delta Two Conundrum
Synopsis
• Current therapeutic γδ T cell options from industry and academic and justification of selected γδ T phenotype
• Is one better than the other or application-dependent
• Towards a rational strategy for choice of phenotype for cancer therapy
10:30 am Panel Discussion: Comparing the Activities of Different γδ T Subsets: Which one is best?
Synopsis
• Outlining the advantages of the γδ 2 subset and their response to phosphoantigens
• Discussing the issues of repeated antigen stimulation with delta 2 and loss of response
• Exploring the potential of the tissue resident delta 1 subset to treat solid tumors
11:00 am Virtual Speed Networking & Morning Break
Synopsis
Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!
Utilizing Innovative Pre-Clinical Models to Maximize Translation into Clinical Trials
12:00 pm Of Mice and Men – Biomimetic Pre-Clinical Modelling of γδT Cell Product Efficacy
Synopsis
• 3D organoid cultures
• Multi-parametric, concurrent analysis of tumour targets and T cell effectors
12:30 pm Maximizing the Clinical Potential of Gamma Delta T Cell-Based Therapies
Synopsis
• Overview of manufacture of gene-modified gamma delta T cells
• Understanding and optimizing activation pathways in gamma delta T cells
• Optimizing the health and persistence of gamma delta T cell therapies and minimizing host versus graft responses
1:00 pm ImmunoTox: Modifying Solid Tumors to Enhance the Gamma Delta T cell Response
Synopsis
• Lentivirus vector modification increases tumor cytotoxicity among Vg9Vd2 T cells
• Complex viral vectors both stimulate and support tumor killing
• Potent tumor destruction is driven by local stimulation that drives tumor infiltration by Vg9Vd2 T cells
1:30 pm Lunch & Networking
Exploring Antibody-Based Approaches for γδ T Activation
2:30 pm Bispecific Antibodies to Engage Vγ9Vδ2-T cells for Cancer Immunotherapy
Synopsis
• Introduction to Vγ9Vδ2-T cells; a unique T cell subset with characteristics that make them well suited for a T cell engager approach.
• The broad anticancer potential of tumor targeted activation of Vγ9Vδ2-T cells using a bispecific antibody approach is illustrated in various settings
3:00 pm Targeting Immunosuppressive γδ1 Tcells in Cancer and Synergies with Other γδ Centric Therapies
Synopsis
• γδ1 T cells with immunosuppressive (IS) properties as therapeutic targets in solid tumors: why and how?
• First in class IS γδ1 T cell targeting monoclonal antibody (LYT-210): development and properties
• How should we be thinking in designing clinical trials in the γδ T cells context: are companion diagnostics a must have?
3:30 pm Afternoon Break & Poster Session
Exploring Antibody-Based Approaches for γδ T Activation
4:00 pm Panel Discussion
4:30 pm Therapeutic Antibodies to Modulate the Activity of Cytotoxic Gamma Delta T Cells In Situ
Synopsis
• Unique range of antibodies that selectively modulate targets on gamma delta T cells
• Antibodies provide a precisely targeted signal to the patient’s gamma delta T cells
• Approaches to modulate tumour-infiltrating gamma delta T cells to augment their cytotoxicity and disrupt the tumour microenvironment
5:00 pm Next-Generation Immunotherpeutics – Selective Recruitment of γδ T Cells by Bispecific Antibodies
Synopsis
• Immunotherapeutic approaches for redirecting pan CD3+ T cells to target cancer is under clinical investigation
• Prototypic bispecific antibody concurrently binds to the Vγ9 chain of the Vγ9Vδ2+γδT cells and to tumor antigens for efficient lysis of tumor cells (in vitro and in vivo).
• Bispecific antibodies selectively activates Vγ9+ γδ T cells and recruits γδT cells into cell-cell conjugate formation with tumor cells.